Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer.
Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer.
复制标题
当前针对癌症患者的SARS-COV-2疫苗接种疗效提高的观点。
DOI：
10.1016/j.ejca.2021.06.008
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Carles M
中科院分区：
文献类型：
--
作者：
Barrière J;Re D;Peyrade F;Carles M
研究表明，患有实体癌或血液恶性肿瘤 (HM) 的患者死于冠状病毒病 19 的风险较高。自全球大流行开始以来，由于抗 SARS-SoV-2 疫苗的加速开发，癌症患者在 2021 年初很快就被优先接种，但这取决于全球范围内的疫苗供应情况非常不平等。早在 2021 年 4 月，就迅速报道了免疫功能低下患者的 SARS-CoV-2 mRNA 疫苗的免疫原性受损，尽管幸运的是，疫苗接种在不增加间隔的情况下似乎普遍有效。然而，令人担忧的是，在接受 HM 随访的患者中，SARS-CoV-2 疫苗接种的体液反应被认为不足，特别是当他们接受抗 CD20 治疗时。因此，应在积极治疗癌症的患者中评估通过加强免疫刺激来提高疫苗接种覆盖率。在这里，我们讨论三种不同的方法：第三剂早期疫苗（重复免疫刺激）、异源初免加强疫苗接种（多模式免疫刺激）和双剂量策略（免疫反应最大化）。目前几乎不存在专门的治疗试验，但似乎很快就有必要进行。
A higher risk of death from coronavirus disease 19 has been shown for patients with solid cancers or haematological malignancies (HM). Thanks to the accelerated development of anti–SARS-SoV-2 vaccines in less than a year since the start of the global pandemic, patients with cancer were quickly prioritised in early 2021 for vaccination, however dependent on the very unequal availability at the global level. Impaired immunogenicity of SARS-CoV-2 mRNA vaccines in immunocompromised patients was rapidly reported as early as April 2021, although the vaccination fortunately appears to be generally effective without increasing the spacing. Worryingly, the humoral response of the SARS-CoV-2 vaccination is, however, considered insufficient in patients followed for HM, in particular when they are on anti-CD20 treatment. Thus, improving vaccination coverage by strengthening immune stimulation should be evaluated in patients under active treatment against cancer. Here, we discuss three different approaches: a third dose of early vaccine (repeated immune stimulation), heterologous prime-boost vaccination (multimodal immune stimulation) and a double-dose strategy (maximisation of immune response). Dedicated therapeutic trials, currently almost non-existent, seem rapidly necessary.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
2.4
作者：
Sanada, Yukinari;Yakushijin, Kimikazu;Minami, Hironobu
通讯作者：
Minami, Hironobu
DOI：
10.1016/j.ejca.2021.03.033
发表时间：
2021-06
期刊：
European journal of cancer (Oxford, England : 1990)
影响因子：
--
作者：
Mansi L;Spehner L;Daguindau E;Bouiller K;Almotlak H;Stein U;Bouard A;Kim S;Klajer E;Jary M;Meynard G;Vienot A;Nardin C;Bazan F;Lepiller Q;Westeel V;Adotévi O;Borg C;Kroemer M
通讯作者：
Kroemer M
影响因子：
8.4
作者：
Elkrief, Arielle;Desilets, Antoine;Routy, Bertrand
通讯作者：
Routy, Bertrand
DOI：
10.1016/j.ejca.2020.09.035
发表时间：
2020-12
期刊：
European journal of cancer (Oxford, England : 1990)
影响因子：
--
作者：
Lièvre A;Turpin A;Ray-Coquard I;Le Malicot K;Thariat J;Ahle G;Neuzillet C;Paoletti X;Bouché O;Aldabbagh K;Michel P;Debieuvre D;Canellas A;Wislez M;Laurent L;Mabro M;Colle R;Hardy-Bessard AC;Mansi L;Colomba E;Bourhis J;Gorphe P;Pointreau Y;Idbaih A;Ursu R;Di Stefano AL;Zalcman G;Aparicio T;GCO-002 CACOVID-19 collaborators/investigators
通讯作者：
GCO-002 CACOVID-19 collaborators/investigators